ESMO: Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
Company Has Begun Rolling Submission
John Haanen presented the Phase III study at ESMO 2022, helping to increase confidence in TILs as a viable option in later line care. • Source: ESMO 
